Tribute Pharmaceuticals Canada Inc. (fka TBUFF)

[Enterprising Investor]

Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction (1/21/16)

MILTON, ONTARIO--(Marketwired - Jan. 21, 2016) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have both recommended that Tribute shareholders vote FOR the special resolution (the "Arrangement Resolution") to approve the previously announced transaction (the "Transaction") with Pozen Inc. ("Pozen") and combination under Aralez Pharmaceuticals Inc. ("Parent"), to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, Toronto, Ontario.

In connection with the Transaction, each Tribute Shareholder will receive 0.1455 of a common share of Parent per Tribute common share ("Tribute Shares").

Both ISS and Glass Lewis are independent proxy advisory firms which, among other services, provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

The Board of Directors of Tribute unanimously recommends that Tribute shareholders vote FOR the Arrangement Resolution.

Shareholders are reminded to vote FOR the Arrangement Resolution prior to the voting deadline on January 28, 2016 at 10 a.m. EST (Toronto time).

Shareholders should now have received, and are urged to carefully review, the Management Information Circular (the "Circular") and accompanying proxy voting materials as they contain important information regarding the Transaction and its benefits to shareholders. Assuming a successful shareholder vote and satisfaction of the other conditions required for completion of the Transaction, closing is expected to occur in early February 2016.

How to Vote

Vote Today. Your vote is important regardless of the number of Tribute Shares you own.

Registered Shareholders

Tribute shareholders who own Tribute Shares directly and which are represented by a physical certificate, may vote via the internet at www.voteproxyonline.com or following the instructions found on their form of proxy.

Non-Registered Shareholders

Tribute shareholders who hold their Tribute Shares through a broker or other intermediary may vote via the internet at www.proxyvote.com or following the other instructions found on their voting instruction form.

The deadline to vote is January 28, 2016 at 10 a.m. EST (Toronto time). However, Tribute Shareholders are encouraged to vote well in advance of the deadline.

Shareholder Questions

Tribute shareholders who have questions or require assistance with voting may contact Laurel Hill Advisory Group, Tribute's proxy solicitation agent, toll-free at 1-877-452-7184 (416-304-0211 collect) or by email at [e-mail].

About Tribute

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. Bilastine is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada.

The Tribute Shares are traded on the TSX Venture Exchange under the symbol "TRX" and quoted on the OTCQX under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

About POZEN

POZEN Inc. is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

http://www.marketwired.com/press-release/leading-independent-advisors-recommend-that-tribute-shareholders-vote-for-transaction-otcqx-tbuff-2089994.htm